Overview

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Status:
Active, not recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) components and to compare envelope binding antibody responses between the different vaccine regimens.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Crucell Holland BV
Janssen Vaccines & Prevention B.V.

Collaborators:

Beth Israel Deaconess Medical Center
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID)
US Military HIV Research Program

Treatments:

Aluminum phosphate
Krestin
Vaccines